type 2 diabetes with dyslipidaemia
Cardiovascular · 2006–2006
2decisions
1medicine
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nicotinic acid use in combination with an HMG CoA reductase inhibitor (statin) in type 2 diabetic patients with dyslipidaemia whose HDL-C levels are inadequately controlled… | Jul 2006 | Not recommended | no section in document |
| nicotinic acid Add-on treatment for type 2 diabetic patients with dyslipidaemia whose HDL-C levels are inadequately controlled despite monotherapy with a statin (defined as… | Jul 2006 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.